NYMC Faculty Publications
Psychiatric Commentary Addressing the Article Titled "Guidance for Switching From Off-Label Antipsychotics to Pimavanserin for Parkinson's Disease Psychosis: An Expert Consensus"
DOI
10.1017/S1092852918001141
Journal Title
CNS Spectrums
First Page
355
Last Page
357
Document Type
Article
Publication Date
December 2018
Department
Psychiatry and Behavioral Sciences
Abstract
Pimavanserin is not curative, but can improve the quality of life remaining for the person with Parkinson's disease who typically has been suffering from this relentless neurodegenerative disease for years. Using pimavanserin effectively requires knowledge not only about the product itself, but also about the treatments pimavanserin is replacing.
Recommended Citation
Citrome, L. L. (2018). Psychiatric Commentary Addressing the Article Titled "Guidance for Switching From Off-Label Antipsychotics to Pimavanserin for Parkinson's Disease Psychosis: An Expert Consensus". CNS Spectrums, 23 (6), 355-357. https://doi.org/10.1017/S1092852918001141
COinS
